TY - JOUR
T1 - Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine
T2 - A retrospective population-based time-dependent cohort study
AU - Yang, Szu Pang
AU - Muo, Chih Hsin
AU - Wang, I. Kuan
AU - Chang, Yen Jung
AU - Lai, Shih Wei
AU - Lee, Cynthia Wei Sheng
AU - Morisky, Donald E.
N1 - Funding Information:
This study was based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health, and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of Bureau of National Health Insurance, Department of Health, or National Health Research Institutes. This study was supported in parts by Executive Yuan National Science Council (NSC 99-2621-M-039-001), Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002), China Medical University Hospital (1MS1 and DMR-101-016), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM104010092), NRPB Stroke Clinical Trial Consortium (MOST 103-2325-B-039-006), Tseng-Lien Lin Foundation, Taichung, Taiwan , Taiwan Brain Disease Foundation, Taipei, Taiwan , Katsuzo and Kiyo Aoshima Memorial Funds, Japan , and National Health Research Institutes (NHRI-102A1-PDCO-1312141). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2015 Elsevier Ireland Ltd.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Aims: We aimed to examine whether morphine treatment is associated with type 2 diabetes mellitus (T2DM) in female breast cancer patients. Methods: We conducted a retrospective cohort analysis of the Longitudinal Health Insurance Database for Catastrophic Illness Patients in Taiwan. A total of 31,112 women with breast cancer without T2DM history during the period 2000-2005 were identified, divided into morphine and non-morphine users (8071 and 23,041 patients, respectively), and the hazard ratios of newly diagnosed T2DM during the period 2005-2010 were calculated. We used a Cox proportional hazard model with time-dependent exposure covariates to estimate the risk of T2DM. The dosage of morphine was counted as defined daily dose and its effect was assessed by multivariable Cox proportional hazard regression controlling age, Charlson comorbidity index, outpatient department visits, antipsychotics, and breast cancer drugs. Results: Morphine users were 1.24 times more likely to suffer from T2DM than non-morphine users (95% CI = 1.04-1.49). Risk increased slightly with the morphine dosage, in patients aged 35-49 years, and with tamoxifen, aromatase inhibitors, and antipsychotics treatment. Conclusions: The incidence of T2DM is associated with morphine treatment in female breast cancer patients. A higher risk was observed in patients aged 35-49 years using higher dose of morphine, and may be increased by tamoxifen and aromatase inhibitors.
AB - Aims: We aimed to examine whether morphine treatment is associated with type 2 diabetes mellitus (T2DM) in female breast cancer patients. Methods: We conducted a retrospective cohort analysis of the Longitudinal Health Insurance Database for Catastrophic Illness Patients in Taiwan. A total of 31,112 women with breast cancer without T2DM history during the period 2000-2005 were identified, divided into morphine and non-morphine users (8071 and 23,041 patients, respectively), and the hazard ratios of newly diagnosed T2DM during the period 2005-2010 were calculated. We used a Cox proportional hazard model with time-dependent exposure covariates to estimate the risk of T2DM. The dosage of morphine was counted as defined daily dose and its effect was assessed by multivariable Cox proportional hazard regression controlling age, Charlson comorbidity index, outpatient department visits, antipsychotics, and breast cancer drugs. Results: Morphine users were 1.24 times more likely to suffer from T2DM than non-morphine users (95% CI = 1.04-1.49). Risk increased slightly with the morphine dosage, in patients aged 35-49 years, and with tamoxifen, aromatase inhibitors, and antipsychotics treatment. Conclusions: The incidence of T2DM is associated with morphine treatment in female breast cancer patients. A higher risk was observed in patients aged 35-49 years using higher dose of morphine, and may be increased by tamoxifen and aromatase inhibitors.
KW - Breast cancer
KW - Cohort analysis
KW - Morphine
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=84955214483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955214483&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2015.10.005
DO - 10.1016/j.diabres.2015.10.005
M3 - Article
C2 - 26515910
AN - SCOPUS:84955214483
SN - 0168-8227
VL - 110
SP - 285
EP - 290
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
IS - 3
ER -
